A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (BLAZE-1)

J2W-MC-PYAB -

The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19, via an injection into a vein. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone.

Trial Summary

Age Range
Conditions the trial is for
COVID-19
What the trial is testing?
Bamlanivimab, Etesevimab
Could I receive a Placebo?
Yes
Enrollment Goal
3307
Trial Dates
Jun 17, 2020 - Feb 21, 2023
How long will I be in the trial?
Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must test positive for COVID-19 within three days before starting the study

  • Participants must have mild to moderate COVID-19 illness

  • Participants may have at least one of the following: Fever, cough, sore throat, not feeling well, headache, muscle pain, digestive symptoms, or shortness of breath when active

Participants Must Not:

  • Participants must not need a machine to help them breathe (ventilator)

  • Mothers must not be breastfeeding

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources